• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

西洛他唑在健康韩国受试者中的群体药效学。

Population pharmacodynamics of cilostazol in healthy Korean subjects.

作者信息

Jung Yun Seob, Chae Dongwoo, Park Kyungsoo

机构信息

Department of Pharmacology, Yonsei University College of Medicine, Seoul 03722, Korea.

Brain Korea 21 Plus Project for Medical Science, Yonsei University, Seoul 03722, Korea.

出版信息

Transl Clin Pharmacol. 2018 Jun;26(2):93-98. doi: 10.12793/tcp.2018.26.2.93. Epub 2018 Jun 18.

DOI:10.12793/tcp.2018.26.2.93
PMID:32055555
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6989258/
Abstract

Cilostazol is used for the treatment of intermittent claudication, ulceration and pain. This study was conducted to develop a population pharmacodynamic (PD) model for cilostazol's closure time (CT) prolongation effect in healthy Korean subjects based on a pharmacokinetic (PK) model previously developed. PD data were obtained from 29 healthy subjects who participated in a study conducted in 2009 at Severance Hospital. The PK model used was a two-compartment model with first order absorption. CT data were best described by a turnover model with a fractional turnover rate constant ( ) inhibited by drug effects (Eff), which were represented by a sigmoid model [Eff = · / ( +γ)] with being maximum drug effect, drug plasma concentration at 50% of , C drug plasma concentrations, and γ the Hill coefficient. For the selected PD model, parameter estimates were 0.613 for , 0.192 for , 730 ng/ml for and 5.137 for γ. Sex and caffeine drinking status significantly influenced the baseline CT, which was 85.36 seconds in male non-caffeine drinkers and increased by 15.5% and 16.4% in females and caffeine drinkers, respectively. The model adequately described the time course of CT. This was the first population PD study for cilostazol's CT prolongation effect in a Korean population.

摘要

西洛他唑用于治疗间歇性跛行、溃疡和疼痛。本研究基于先前建立的药代动力学(PK)模型,旨在为健康韩国受试者建立西洛他唑闭合时间(CT)延长效应的群体药效学(PD)模型。PD数据来自2009年在延世大学Severance医院进行的一项研究中的29名健康受试者。所使用的PK模型是具有一级吸收的二室模型。CT数据最好用一个周转模型来描述,该模型具有一个受药物效应(Eff)抑制的分数周转率常数( ),药物效应由一个S形模型[Eff = · / ( +γ)]表示,其中 为最大药物效应, 为 的50%时的药物血浆浓度,C为药物血浆浓度,γ为希尔系数。对于所选的PD模型,参数估计值为 时 为0.613 , 为0.192, 为730 ng/ml,γ为5.137。性别和咖啡因饮用状况对基线CT有显著影响,男性非咖啡因饮用者的基线CT为85.36秒,女性和咖啡因饮用者分别增加了15.5%和16.4%。该模型充分描述了CT的时间进程。这是韩国人群中关于西洛他唑CT延长效应的第一项群体PD研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf6f/6989258/d9e6b77ccf07/tcp-26-93-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf6f/6989258/2d5c4c73700c/tcp-26-93-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf6f/6989258/99b0d4a45c1f/tcp-26-93-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf6f/6989258/d9e6b77ccf07/tcp-26-93-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf6f/6989258/2d5c4c73700c/tcp-26-93-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf6f/6989258/99b0d4a45c1f/tcp-26-93-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf6f/6989258/d9e6b77ccf07/tcp-26-93-g003.jpg

相似文献

1
Population pharmacodynamics of cilostazol in healthy Korean subjects.西洛他唑在健康韩国受试者中的群体药效学。
Transl Clin Pharmacol. 2018 Jun;26(2):93-98. doi: 10.12793/tcp.2018.26.2.93. Epub 2018 Jun 18.
2
Sex specificity in methadone analgesia in the rat: a population pharmacokinetic and pharmacodynamic approach.大鼠美沙酮镇痛的性别特异性:群体药代动力学和药效学方法。
Pharm Res. 2002 Jun;19(6):858-67. doi: 10.1023/a:1016117218760.
3
Integrated pharmacokinetic-pharmacodynamic model for acetaminophen, ibuprofen, and placebo antipyresis in children.对乙酰氨基酚、布洛芬和安慰剂在儿童中解热作用的药代动力学-药效学整合模型
J Pharmacokinet Biopharm. 1998 Oct;26(5):559-79. doi: 10.1023/a:1023225217108.
4
Parameter estimation for sigmoid E models in exposure-response relationship.暴露-反应关系中S形E模型的参数估计
Transl Clin Pharmacol. 2017 Jun;25(2):74-84. doi: 10.12793/tcp.2017.25.2.74. Epub 2017 Jun 15.
5
Pharmacokinetic modeling analysis of cilostazol and its active metabolites (OPC-13015 and OPC-13213) after multiple oral doses of cilostazol in healthy Korean volunteers.在健康韩国志愿者中多次口服西洛他唑后,西洛他唑及其活性代谢物(OPC-13015和OPC-13213)的药代动力学建模分析。
Xenobiotica. 2020 Mar;50(3):288-296. doi: 10.1080/00498254.2019.1629042. Epub 2019 Jul 3.
6
Pharmacokinetic-pharmacodynamic study of apomorphine's effect on growth hormone secretion in healthy subjects.阿扑吗啡对健康受试者生长激素分泌影响的药代动力学-药效学研究。
Fundam Clin Pharmacol. 2003 Aug;17(4):473-81. doi: 10.1046/j.1472-8206.2003.00152.x.
7
Pharmacokinetic-Pharmacodynamic Modelling of the antipyretic effect of two oral formulations of ibuprofen.两种布洛芬口服制剂解热作用的药代动力学-药效学建模
Clin Pharmacokinet. 2000 Jun;38(6):505-18. doi: 10.2165/00003088-200038060-00004.
8
Population pharmacodynamics: strategies for concentration-and effect-controlled clinical trials.群体药效学:浓度和效应控制临床试验策略
Ann Pharmacother. 1996 Jan;30(1):12-9. doi: 10.1177/106002809603000102.
9
Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).使用混合效应模型(NONMEM)对血小板糖蛋白IIb/IIIa拮抗剂静脉注射RGD891进行药代动力学和浓度-效应分析。
J Clin Pharmacol. 2000 Oct;40(10):1129-40.
10
Pharmacokinetic-pharmacodynamic (PK-PD) modeling for a new antihypertensive agent (neutral metalloendopeptidase inhibitor SCH 42354) in patients with mild to moderate hypertension.
Eur J Clin Pharmacol. 1995;48(5):351-9. doi: 10.1007/BF00194950.

引用本文的文献

1
Incorporating new approach methods (NAMs) data in dose-response assessments: The future is now!将新方法(NAMs)数据纳入剂量反应评估:未来已来!
J Toxicol Environ Health B Crit Rev. 2025 Jan 2;28(1):28-62. doi: 10.1080/10937404.2024.2412571. Epub 2024 Oct 10.
2
Cilostazol for Secondary Stroke Prevention: History, Evidence, Limitations, and Possibilities.西洛他唑用于二级卒中预防:历史、证据、局限性和可能性。
Stroke. 2021 Oct;52(10):e635-e645. doi: 10.1161/STROKEAHA.121.035002. Epub 2021 Sep 14.

本文引用的文献

1
Mechanistic Model for Blood Pressure and Heart Rate Changes Produced by Telmisartan in Human Beings.替米沙坦在人体中引起的血压和心率变化的机制模型。
Basic Clin Pharmacol Toxicol. 2018 Jan;122(1):139-148. doi: 10.1111/bcpt.12856. Epub 2017 Sep 6.
2
Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy.西洛他唑可能预防接受抗血小板治疗患者的心源性栓塞性卒中。
Neurol Res. 2015 Jul;37(7):619-23. doi: 10.1179/1743132815Y.0000000021. Epub 2015 Mar 23.
3
Platelet function tests: a comparative review.血小板功能检测:一项比较性综述。
Vasc Health Risk Manag. 2015 Feb 18;11:133-48. doi: 10.2147/VHRM.S44469. eCollection 2015.
4
Population pharmacokinetic analysis of diurnal and seasonal variations of plasma concentrations of cilostazol in healthy volunteers.健康志愿者中西洛他唑血浆浓度昼夜及季节变化的群体药代动力学分析
Ther Drug Monit. 2014 Dec;36(6):771-80. doi: 10.1097/FTD.0000000000000077.
5
Gender, race and diet affect platelet function tests in normal subjects, contributing to a high rate of abnormal results.性别、种族和饮食会影响正常受试者的血小板功能检测,导致异常结果的比例较高。
Br J Haematol. 2014 Jun;165(6):842-53. doi: 10.1111/bjh.12827. Epub 2014 Mar 12.
6
Semi-mechanistic modelling and simulation of inhibition of platelet aggregation by antiplatelet agents.抗血小板药物抑制血小板聚集的半机制建模与模拟
Basic Clin Pharmacol Toxicol. 2014 Oct;115(4):352-9. doi: 10.1111/bcpt.12222. Epub 2014 Mar 29.
7
Basic concepts in population modeling, simulation, and model-based drug development: part 3-introduction to pharmacodynamic modeling methods.群体建模、模拟和基于模型的药物研发的基本概念:第 3 部分——药效学建模方法介绍。
CPT Pharmacometrics Syst Pharmacol. 2014 Jan 2;3(1):e88. doi: 10.1038/psp.2013.71.
8
Mechanism-based pharmacodynamic modeling.基于机制的药效学建模。
Methods Mol Biol. 2012;929:583-600. doi: 10.1007/978-1-62703-050-2_21.
9
Pharmacokinetic comparison of sustained- and immediate-release oral formulations of cilostazol in healthy Korean subjects: a randomized, open-label, 3-part, sequential, 2-period, crossover, single-dose, food-effect, and multiple-dose study.在健康韩国受试者中比较西洛他唑持续释放和即刻释放口服制剂的药代动力学:一项随机、开放标签、3 部分、序贯、2 周期、交叉、单次、食物效应和多次给药研究。
Clin Ther. 2011 Dec;33(12):2038-53. doi: 10.1016/j.clinthera.2011.10.024. Epub 2011 Nov 29.
10
Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and ABCB1.健康受试者中细胞色素 P4503A5、CYP2C19 和 ABCB1 基因多态性对西洛他唑的群体药代动力学分析。
Br J Clin Pharmacol. 2010 Jan;69(1):27-37. doi: 10.1111/j.1365-2125.2009.03558.x.